InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -34.06% | -6.73% | -3.27% | 7.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -34.06% | -6.73% | -3.27% | 7.50% |
| Cost of Revenue | -- | -39.57% | -21.88% | -27.56% | -28.28% |
| Gross Profit | -- | -58.65% | -55.38% | -33.91% | 2.63% |
| SG&A Expenses | -- | -6.15% | -9.55% | -2.56% | 0.03% |
| Depreciation & Amortization | -- | -1.87% | -2.99% | -3.87% | -3.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -9.93% | -11.97% | -6.20% | -8.88% |
| Operating Income | -- | -6.95% | -1.57% | -9.77% | 2.09% |
| Income Before Tax | -- | -1.59% | 2.48% | -21.26% | -7.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -1.50% | 2.56% | -21.13% | -6.94% |
| Earnings from Discontinued Operations | -- | -138.03% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -2.38% | 3.15% | -20.46% | -6.34% |
| EBIT | -- | -6.95% | -1.57% | -9.77% | 2.09% |
| EBITDA | -- | -7.24% | -1.73% | -10.22% | 2.03% |
| EPS Basic | -- | 76.62% | 70.77% | 48.59% | 64.31% |
| Normalized Basic EPS | -- | 76.60% | 70.52% | 48.32% | 64.17% |
| EPS Diluted | -- | 76.62% | 70.77% | 48.59% | 64.31% |
| Normalized Diluted EPS | -- | 76.60% | 70.52% | 48.32% | 64.17% |
| Average Basic Shares Outstanding | -- | 363.37% | 358.96% | 266.24% | 156.59% |
| Average Diluted Shares Outstanding | -- | 363.37% | 358.96% | 266.24% | 156.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |